Small-molecule modulators of tumor necrosis factor signaling

Henri Chédotal; Dilip Narayanan; Katrine Povlsen; Charlotte H. Gotfredsen; Roberta Brambilla; Michael Gajhede; Anders Bach; Mads H. Clausen

doi:10.1016/j.drudis.2023.103575

Small-molecule modulators of tumor necrosis factor signaling

Henri Chédotal, Dilip Narayanan, Katrine Povlsen, Charlotte H. Gotfredsen, Roberta Brambilla, Michael Gajhede, Anders Bach, Mads H. Clausen

Research output: Contribution to journal › Review › Research › peer-review

37 Downloads (Pure)

Abstract

Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer's disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.

Original language	English
Article number	103575
Journal	Drug Discovery Today
Volume	28
Issue number	6
ISSN	1359-6446
DOIs	https://doi.org/10.1016/j.drudis.2023.103575
Publication status	Published - 2023

Bibliographical note

Access to Document

10.1016/j.drudis.2023.103575

FulltextFinal published version, 1.6 MBLicence: CC BY

Cite this

@article{0c7772f0d6e5422a8852032c535e3320,

title = "Small-molecule modulators of tumor necrosis factor signaling",

abstract = "Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer's disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.",

author = "Henri Ch{\'e}dotal and Dilip Narayanan and Katrine Povlsen and Gotfredsen, {Charlotte H.} and Roberta Brambilla and Michael Gajhede and Anders Bach and Clausen, {Mads H.}",

year = "2023",

doi = "10.1016/j.drudis.2023.103575",

language = "English",

volume = "28",

journal = "Drug Discovery Today: BIOSILICO",

issn = "1359-6446",

publisher = "Elsevier Ltd. * Trends Journals",

number = "6",

}

TY - JOUR

T1 - Small-molecule modulators of tumor necrosis factor signaling

AU - Chédotal, Henri

AU - Narayanan, Dilip

AU - Povlsen, Katrine

AU - Gotfredsen, Charlotte H.

AU - Brambilla, Roberta

AU - Gajhede, Michael

AU - Bach, Anders

AU - Clausen, Mads H.

PY - 2023

Y1 - 2023

N2 - Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer's disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.

AB - Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer's disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.

U2 - 10.1016/j.drudis.2023.103575

DO - 10.1016/j.drudis.2023.103575

M3 - Review

C2 - 37003513

VL - 28

JO - Drug Discovery Today: BIOSILICO

JF - Drug Discovery Today: BIOSILICO

SN - 1359-6446

IS - 6

M1 - 103575

ER -